Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHERYL M MARKS

Allopathic & Osteopathic Physicians Anesthesiology

NPI
1891818613
CMS profile
559245
Location
RENTON, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$180.86

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $148.59 3
Education $32.27 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Novo Nordisk Inc $113.04 2
Boehringer Ingelheim Pharmaceuticals, Inc. $48.02 1
Insulet Corporation $19.80 1

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHERYL M MARKS

NPI 1891818613 · CMS profile ID 559245

Allopathic & Osteopathic Physicians / Anesthesiology

RENTON, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1891818613?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHERYL M MARKS, NPI 1891818613, CMS profile ID 559245. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891818613?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). SHERYL M MARKS, NPI 1891818613, CMS profile ID 559245. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891818613?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
SHERYL M MARKS, NPI 1891818613, CMS profile ID 559245, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1891818613?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $180.86 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $32.2711/07/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1188708330 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $48.0210/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223049550 CMS
Novo Nordisk Inc $80.7704/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188359046 CMS
Insulet Corporation $19.8004/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207082027 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2023 $1,871.98 13
PY2024 $1,439.58 11
PY2025 $180.86 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,686,456.51 59
PY2024 Recipient $3,530.00 1
PY2024 Principal investigator $2,304,975.64 50
PY2023 Principal investigator $442,298.83 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

59 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eli Lilly and Company $80.00 12/31/2025 Non-covered Recipient Entity
RAINIER CLINICAL RESEARCH CENTER
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1187888362
Principal investigator 1 ROCHE DIABETES CARE, INC. $551,067.00 12/11/2025 Non-covered Recipient Entity
RAINIER CRC
RD007461 No dispute reported 06/30/2026 1185585199
Principal investigator 1 ModernaTX, Inc. $6,414.21 12/01/2025 Non-covered Recipient Entity
RAINER CRC LLC DBA RAINER CLIN
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989300
Principal investigator 1 Eli Lilly and Company $1,020.92 11/19/2025 Non-covered Recipient Entity
RAINIER CLINICAL RESEARCH CENTER INC
RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY4065967 FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187889192
Principal investigator 1 ROCHE DIABETES CARE, INC. $9.60 10/29/2025 Non-covered Recipient Entity
RAINIER CRC
RD007461 No dispute reported 06/30/2026 1185585181
Principal investigator 1 ROCHE DIABETES CARE, INC. $20,700.00 10/29/2025 Non-covered Recipient Entity
RAINIER CRC
RD007461 No dispute reported 06/30/2026 1185585213
Principal investigator 1 Dexcom, Inc. $11,450.00 10/28/2025 Non-covered Recipient Entity
Rainier Clinical Research Center
MULTI-SESSION EVALUATION OF THE INVESTIGATIONAL DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM IN ADULT PARTICIPANTS No dispute reported 06/30/2026 1250961994
Principal investigator 1 ModernaTX, Inc. $3,610.27 10/24/2025 Non-covered Recipient Entity
RAINER CRC LLC DBA RAINER CLIN
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989290
Principal investigator 1 ROCHE DIABETES CARE, INC. $5,688.90 10/21/2025 Non-covered Recipient Entity
RAINIER CRC
RD007461 No dispute reported 06/30/2026 1185585207
Principal investigator 1 Eli Lilly and Company $41,297.00 10/10/2025 Non-covered Recipient Entity
RAINIER CLINICAL RESEARCH CENTER INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF MUVALAPLIN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE HAD A PRIOR ATHEROSCLEROTIC CARDIOVASCULAR EVENT OR ARE AT RISK FOR A FIRST ATHEROSCLEROTIC CARDIOVASCULAR EVENT – MOVE-LP(A) No dispute reported 06/30/2026 1187888748
Principal investigator 1 ROCHE DIABETES CARE, INC. $12,788.10 10/09/2025 Non-covered Recipient Entity
RAINIER CRC
RD007461 No dispute reported 06/30/2026 1185585239
Principal investigator 1 ModernaTX, Inc. $5,614.16 09/26/2025 Non-covered Recipient Entity
RAINER CRC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989304
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,320.13 09/24/2025 Non-covered Recipient Entity
Rainier Clinical Research Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 2) No dispute reported 06/30/2026 1235994369
Principal investigator 1 ROCHE DIABETES CARE, INC. $0.24 09/23/2025 Non-covered Recipient Entity
RAINIER CRC
RD007461 No dispute reported 06/30/2026 1185585201
Principal investigator 1 ROCHE DIABETES CARE, INC. $299,000.00 09/18/2025 Non-covered Recipient Entity
RAINIER CRC
RD007461 No dispute reported 06/30/2026 1185585189
Principal investigator 1 Dexcom, Inc. $3,500.00 09/09/2025 Non-covered Recipient Entity
Rainier Clinical Research Center
MULTI-SESSION EVALUATION OF THE INVESTIGATIONAL DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SENSOR IN ADULT AND PEDIATRIC PARTICIPANTS No dispute reported 06/30/2026 1250961990
Principal investigator 1 ModernaTX, Inc. $13,630.98 08/27/2025 Non-covered Recipient Entity
RAINER CRC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989292
Principal investigator 1 Eli Lilly and Company $35.67 08/26/2025 Non-covered Recipient Entity
RAINIER CLINICAL RESEARCH CENTER
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187888364
Principal investigator 1 ROCHE DIABETES CARE, INC. $1,079.00 08/25/2025 Non-covered Recipient Entity
RAINIER CRC
RD007461 No dispute reported 06/30/2026 1185585217
Principal investigator 1 ROCHE DIABETES CARE, INC. $2,190.00 08/22/2025 Non-covered Recipient Entity
RAINIER CRC
RD007461 No dispute reported 06/30/2026 1185585229
Principal investigator 1 AstraZeneca Pharmaceuticals LP $131,307.85 07/31/2025 Non-covered Recipient Entity
RAINIER CLINICAL RESEARCH CENTER
A Phase IIb Randomised, Double-blind, Placebocontrolled Study to Evaluate the Efficacy, Safety and Tolerability of Coadministration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight with Co-morbidity (ASCEND) No dispute reported 06/30/2026 1185544887
Principal investigator 1 ModernaTX, Inc. $1,404.48 07/25/2025 Non-covered Recipient Entity
RAINER CRC LLC DBA RAINER CLIN
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989308
Principal investigator 1 ROCHE DIABETES CARE, INC. $10,535.93 07/22/2025 Non-covered Recipient Entity
RAINIER CRC
RD007461 No dispute reported 06/30/2026 1185585195
Principal investigator 1 ROCHE DIABETES CARE, INC. $55.00 07/18/2025 Non-covered Recipient Entity
RAINIER CRC
RD007461 No dispute reported 06/30/2026 1185585209
Principal investigator 1 ROCHE DIABETES CARE, INC. $72,687.89 07/17/2025 Non-covered Recipient Entity
RAINIER CRC
RD007461 No dispute reported 06/30/2026 1185585241
Principal investigator 1 ROCHE DIABETES CARE, INC. $403.20 07/16/2025 Non-covered Recipient Entity
RAINIER CRC
RD007461 No dispute reported 06/30/2026 1185585203
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $15,150.40 07/14/2025 Non-covered Recipient Entity
Rainier Clinical Research Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 2) No dispute reported 06/30/2026 1235994371
Principal investigator 1 ROCHE DIABETES CARE, INC. $7,113.46 07/14/2025 Non-covered Recipient Entity
RAINIER CRC
RD007461 No dispute reported 06/30/2026 1185585219
Principal investigator 1 ROCHE DIABETES CARE, INC. $38,587.37 07/14/2025 Non-covered Recipient Entity
RAINIER CRC
RD007461 No dispute reported 06/30/2026 1185585233
Principal investigator 1 ModernaTX, Inc. $49,191.60 07/07/2025 Non-covered Recipient Entity
RAINER CRC LLC DBA RAINER CLIN
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252989280
Principal investigator 1 ModernaTX, Inc. $59,041.45 07/07/2025 Non-covered Recipient Entity
RAINER CRC LLC DBA RAINER CLIN
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252989298
Principal investigator 1 ModernaTX, Inc. $55,590.65 07/02/2025 Non-covered Recipient Entity
RAINER CRC LLC DBA RAINER CLIN
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252989286
Principal investigator 1 Dexcom, Inc. $350.00 07/01/2025 Non-covered Recipient Entity
Rainier Clinical Research Center
MULTI-SESSION EVALUATION OF THE INVESTIGATIONAL DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SENSOR IN ADULT AND PEDIATRIC PARTICIPANTS No dispute reported 06/30/2026 1250961992
Principal investigator 1 ModernaTX, Inc. $8,219.97 06/25/2025 Non-covered Recipient Entity
RAINER CRC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989296
Principal investigator 1 ModernaTX, Inc. $135,521.25 06/13/2025 Non-covered Recipient Entity
RAINER CRC LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252989282
Principal investigator 1 ModernaTX, Inc. $1,500.00 06/13/2025 Non-covered Recipient Entity
RAINER CRC LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252989284
Principal investigator 1 Dexcom, Inc. $1,012.00 06/03/2025 Non-covered Recipient Entity
Rainier Clinical Research Center
MULTI-SESSION EVALUATION OF THE INVESTIGATIONAL DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SENSOR IN ADULT AND PEDIATRIC PARTICIPANTS No dispute reported 06/30/2026 1250961986
Principal investigator 1 ROCHE DIABETES CARE, INC. $182,839.00 06/03/2025 Non-covered Recipient Entity
RAINIER CRC
DC000145 No dispute reported 06/30/2026 1185585227
Principal investigator 1 ModernaTX, Inc. $10,222.61 05/28/2025 Non-covered Recipient Entity
RAINER CRC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989294
Principal investigator 1 ROCHE DIABETES CARE, INC. $85,379.00 05/15/2025 Non-covered Recipient Entity
RAINIER CRC
DC000145 No dispute reported 06/30/2026 1185585185
Principal investigator 1 ROCHE DIABETES CARE, INC. $100,000.00 05/15/2025 Non-covered Recipient Entity
RAINIER CRC
DC000145 No dispute reported 06/30/2026 1185585211
Principal investigator 1 Dexcom, Inc. $56,629.00 05/06/2025 Non-covered Recipient Entity
Rainier Clinical Research Center
MULTI-SESSION EVALUATION OF THE INVESTIGATIONAL DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SENSOR IN ADULT AND PEDIATRIC PARTICIPANTS No dispute reported 06/30/2026 1250961988
Principal investigator 1 ModernaTX, Inc. $4,470.91 05/01/2025 Non-covered Recipient Entity
RAINER CRC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989288
Principal investigator 1 Eli Lilly and Company $165.00 04/30/2025 Non-covered Recipient Entity
RAINIER CLINICAL RESEARCH CENTER INC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) No dispute reported 06/30/2026 1187887916
Principal investigator 1 Eli Lilly and Company $173.50 04/30/2025 Non-covered Recipient Entity
RAINIER CLINICAL RESEARCH CENTER INC
A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187888370
Principal investigator 1 Eli Lilly and Company $1,939.36 04/23/2025 Non-covered Recipient Entity
RAINIER CLINICAL RESEARCH CENTER INC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1187888366
Principal investigator 1 ModernaTX, Inc. $4,612.21 04/01/2025 Non-covered Recipient Entity
RAINER CRC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989302
Principal investigator 1 Eli Lilly and Company $4,750.00 03/24/2025 Non-covered Recipient Entity
RAINIER CLINICAL RESEARCH CENTER
A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187888360
Principal investigator 1 ModernaTX, Inc. $46.20 03/03/2025 Non-covered Recipient Entity
RAINER CRC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989310
Principal investigator 1 ModernaTX, Inc. $13,830.37 03/03/2025 Non-covered Recipient Entity
RAINER CRC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989314
Principal investigator 1 ModernaTX, Inc. $25,155.00 02/21/2025 Non-covered Recipient Entity
RAINER CRC LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252989306
Principal investigator 1 Dexcom, Inc. $31,250.00 02/04/2025 Non-covered Recipient Entity
Rainier Clinical Research Center
MULTI-SESSION EVALUATION OF THE INVESTIGATIONAL DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SENSOR IN ADULT AND PEDIATRIC PARTICIPANTS No dispute reported 06/30/2026 1250961984
Principal investigator 1 Eli Lilly and Company $195.00 01/31/2025 Non-covered Recipient Entity
RAINIER CLINICAL RESEARCH CENTER
A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187888578
Principal investigator 1 Eli Lilly and Company $415.70 01/31/2025 Non-covered Recipient Entity
RAINIER CLINICAL RESEARCH CENTER
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) No dispute reported 06/30/2026 1187889186
Principal investigator 1 ROCHE DIABETES CARE, INC. $100,000.00 01/30/2025 Non-covered Recipient Entity
RAINIER CRC
DC000145 No dispute reported 06/30/2026 1185585231
Principal investigator 1 ModernaTX, Inc. $7,419.92 01/29/2025 Non-covered Recipient Entity
RAINER CRC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252989312
Principal investigator 1 Eli Lilly and Company $9,867.71 01/27/2025 Non-covered Recipient Entity
RAINIER CLINICAL RESEARCH CENTER INC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187888384
Principal investigator 1 Eli Lilly and Company $189,610.34 01/07/2025 Non-covered Recipient Entity
RAINIER CLINICAL RESEARCH CENTER
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) No dispute reported 06/30/2026 1187888742
Principal investigator 1 Eli Lilly and Company $289,317.00 01/07/2025 Non-covered Recipient Entity
RAINIER CLINICAL RESEARCH CENTER
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187888744